Cognito therapeutics, inc.

Cognito Therapeutics, Inc. is a company that is dedicated to advancing the field of neuromodulation to create novel therapeutics that improve the lives of patients living with neurodegenerative diseases. The company was founded in 2016 by Dr. Brent Vaughan and Dr. Khosrow Behbehani, two experts in the field of neuroscience who saw an opportunity to use their knowledge and expertise to make a real difference in the lives of people suffering from these debilitating conditions.

Neurodegenerative diseases are a group of disorders that affect the nervous system and cause progressive damage to nerve cells, leading to a range of symptoms such as memory loss, cognitive decline, and movement disorders. These conditions include Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and others.

Despite decades of research into these conditions, there are still no cures for most neurodegenerative diseases. Current treatments focus on managing symptoms rather than addressing the underlying causes of these conditions. This is where Cognito Therapeutics comes in - by developing new therapies that target specific areas of the brain affected by these diseases.

The company's approach involves using non-invasive neuromodulation techniques such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) to stimulate or inhibit specific regions of the brain involved in cognitive function or motor control. By doing so, they hope to improve symptoms such as memory loss or tremors associated with neurodegenerative diseases.

One area where Cognito Therapeutics is making significant progress is in Alzheimer's disease research. The company has developed a novel therapy called GammaSense™ which uses TMS technology to stimulate gamma oscillations in specific regions of the brain associated with memory formation and retrieval. Gamma oscillations are thought to play an important role in learning and memory processes - by enhancing them through TMS therapy; Cognito hopes to improve cognitive function in patients with Alzheimer's disease.

Another area where Cognito Therapeutics is making strides is Parkinson's disease research - specifically focusing on gait disturbances associated with this condition. The company has developed a wearable device called GaitThru™ which uses tDCS technology combined with motion sensors placed on shoes or clothing worn by patients during walking exercises designed specifically for Parkinson’s Disease patients who have difficulty walking due their condition . This device aims at improving gait stability while reducing falls risk among PD patients

Cognito Therapeutics' innovative approach has attracted attention from investors as well as researchers around world . In 2020 alone ,the Company raised $113 million dollars from investors including ARCH Venture Partners , Flagship Pioneering , Polaris Partners among others .

In conclusion,Cognito therapeutics inc.,is one-of-a-kind biotech firm focused on developing innovative therapies for neurodegenerative disorders using non-invasive neuromodulation techniques like TMS & tDCS . With its cutting-edge technologies like GammaSense™ & GaitThru™ devices it aims at improving quality life for millions suffering from neurological disorders worldwide .